Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Backstop Price Caps in Commercial Health Care Markets

Backstop Price Caps in Commercial Health Care Markets Letters data contributors, Aetna, Humana, and UnitedHealthcare, in providing the with SCD, and a reduction from 14.8% to 11.4% (3.4- claims data analyzed in this study. percentage-point difference [95% CI, 1.0-5.9]; P = .005) Role of the Funder/Sponsor: NIDA and CDC had no role in the design and among patients with cancer with bone metastasis (Figure 1). conduct of the study; collection, management, analysis, and interpretation of Comprehensive mandates were associated with a reduction the data; preparation, review, or approval of the manuscript; and decision to in mean MMEs dispensed from 688.3 to 366.5 (difference, submit the manuscript for publication. 321.8 [95% CI, 51.5-592.2]; P = .003) to patients with SCD Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the opinions of NIDA or CDC. (Figure 2) but no change in MMEs for patients with cancer with bone metastasis. Noncomprehensive mandates were Meeting Presentation: Presented virtually at the annual research meeting of AcademyHealth, June 14, 2021. not associated with significant changes in either outcome. Additional Contributions: Philip J. Jeng, MS, conducted original legal research of PDMP policies. Michelle Papp provided editorial and administrative Discussion | Comprehensive PDMP mandates were associated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Backstop Price Caps in Commercial Health Care Markets

JAMA , Volume 326 (3) – Jul 20, 2021

Loading next page...
 
/lp/american-medical-association/backstop-price-caps-in-commercial-health-care-markets-DJYwm04uEZ
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.6809
Publisher site
See Article on Publisher Site

Abstract

Letters data contributors, Aetna, Humana, and UnitedHealthcare, in providing the with SCD, and a reduction from 14.8% to 11.4% (3.4- claims data analyzed in this study. percentage-point difference [95% CI, 1.0-5.9]; P = .005) Role of the Funder/Sponsor: NIDA and CDC had no role in the design and among patients with cancer with bone metastasis (Figure 1). conduct of the study; collection, management, analysis, and interpretation of Comprehensive mandates were associated with a reduction the data; preparation, review, or approval of the manuscript; and decision to in mean MMEs dispensed from 688.3 to 366.5 (difference, submit the manuscript for publication. 321.8 [95% CI, 51.5-592.2]; P = .003) to patients with SCD Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the opinions of NIDA or CDC. (Figure 2) but no change in MMEs for patients with cancer with bone metastasis. Noncomprehensive mandates were Meeting Presentation: Presented virtually at the annual research meeting of AcademyHealth, June 14, 2021. not associated with significant changes in either outcome. Additional Contributions: Philip J. Jeng, MS, conducted original legal research of PDMP policies. Michelle Papp provided editorial and administrative Discussion | Comprehensive PDMP mandates were associated

Journal

JAMAAmerican Medical Association

Published: Jul 20, 2021

References